NCT00397527
Completed
Phase 3
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up of Dermacyd Wipes
ConditionsHygiene
Drugslactoserum
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Hygiene
- Sponsor
- Sanofi
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Adverse events and their association with the treatment.
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to demonstrate the safety of the gynecological formulation in normal and usual usage condition of Dermacyd Wipes
Investigators
Eligibility Criteria
Inclusion Criteria
- •Integral skin in the tested region
Exclusion Criteria
- •Pregnancy or breastfeeding women;
- •Use of antiinflammatory or immunosuppression drugs;
- •Topical medication use at the region to be treated;
- •Cutaneous disease or active gynaecological disease which may interfer in study results;
- •Personal history of allergic disease at the area to be treated;
- •Allergic or atopic history.
Outcomes
Primary Outcomes
Adverse events and their association with the treatment.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Acceptability Dermacyd Delicata - New Fragrance - Lactoserum - HygieneHygieneNCT00370162Sanofi30
Completed
Phase 4
Acceptability Lactoserum (Dermacyd Delicata - New Fragrance)HygieneNCT00497783Sanofi30
Completed
Phase 4
Acceptability of Lactacyd FeminaHygieneNCT00712868Sanofi559
Completed
Phase 4
Dermacyd Infantile - Acceptability.HygieneNCT00881270Sanofi31
Completed
Phase 3
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet FlowerHygieneNCT00663273Sanofi30